MPGN type I induced by granulocyte colony stimulating factor.
We report a girl with severe congenital neutropenia who has received long-term granulocyte-colony stimulating factor (G-CSF) therapy and has developed macroscopic hematuria, proteinuria, and decreased renal function associated with biopsy-proven membranoproliferative glomerulonephritis (MPGN) type I. Temporary discontinuation of G-CSF therapy as well as the use of glycosylated G-CSF has resulted in improvement in renal manifestations. We postulate that the MPGN was G-CSF-induced. Long-term G-CSF therapy should be used with great caution and close surveillance of kidney function.
Magen
Daniella
D
Pediatric Nephrology Unit, Rambam Medical Center, P.O. Box 9602, Haifa 31096, Israel. d_magen@rambam.health.gov.il
Mandel
Hana
H
Berant
Moshe
M
Ben-Izhak
Ofer
O
Zelikovic
Israel
I
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000293:Adolescent; D004334:Drug Administration Schedule; D005260:Female; D015432:Glomerulonephritis, Membranoproliferative / Q000139:chemically induced* / Q000473:pathology; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D000078224:Lenograstim; D009503:Neutropenia / Q000151:congenital / Q000188:drug therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D019233:Retreatment
D000276:Adjuvants, Immunologic; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim